Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine Dimesylate in children and adolescents with ADHD
NCT00763971Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Nov 2008; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00763971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00763971.